Accentus Medical Wins Major Technology Innovation Award

31 October 2008

Accentus Medical is proud to announce that it has been presented with a major award from the London Technology Fund, Londons specialist investor in new technology companies. At an Awards Ceremony in London on 29th October, the company was declared winner of the Life Sciences sector award, and also the overall Grand Prix. The winning formula was innovative technology, a clear market need and a strong management team. The Awards were the culmination of an eight-month programme which started with 150 companies and involved 40 shortlisted companies in a programme of training and advice designed to prepare for investment and build relationships with major technology corporates.

Philip Agg, Chief Executive of Accentus Medical, received the Grand Prix award from Dr David Bott, Director of Innovation Programmes, Technology Strategy Board. Philip stated: "We are delighted to be sector winners and the overall winner of the Grand Prix, and we are very grateful to the London Technology Fund for the opportunity to participate in this innovative and prestigious competition. The training workshops have been an excellent source of information and knowledge for our management team, providing us with the essential business toolkit as we embark on the exciting journey of growing the company, delivering excellent products to our customers and building value for our investors."

Martin Pickford, Managing Director of Accentus Medical and co-inventor of the companys breakthrough AglunaŽ technology, stated: "This award is a tribute to the whole team who have worked so hard in developing the company since its formation in 2001. We are particularly excited about the commercial potential for AglunaŽ, an innovative technology utilising the biocidal properties of silver with the aim of reducing the risk of post-operative infection in surgical implants such as joint replacements, pacemakers and dental implants. This proprietary technology continues to demonstrate very encouraging results in its use with patient specific megaprostheses, manufactured by our licensee Stanmore Implants Worldwide, and is starting to create widespread interest within the orthopaedic and broader medical device industry."

For a full press release from the London Technology Fund, visit the following link:

Contact Us

T: +44 (0)1235 434 320
F: +44 (0)1235 434 329